Is Syncom Formul. overvalued or undervalued?

As of 11 September 2025, the valuation grade for Syncom Formul. has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 29.44, an EV to EBITDA of 26.59, and a ROCE of 19.43%.
When compared to peers, Syncom Formul.'s PE ratio is lower than Sun Pharma's 33.62 but significantly higher than Cipla's 23.38, suggesting that while it is less expensive than some competitors, it remains in the upper echelon of valuation within its industry. The PEG ratio of 0.29 also indicates that the stock may be overvalued relative to its growth prospects. Recent stock performance shows that while Syncom Formul. has outperformed the Sensex over the last three years, it has underperformed year-to-date and over the past year, reinforcing concerns about its current valuation.